癌化特性之分析套組-Tube formation kit

In Vitro體外血管新生分析套組 | Tube formation kit In Vitro Angiogenesis貨號3470-096-K

Trevigen(R&D)提供 Cultrex® In Vitro Angiogenesis Assay Kit ，可以偵測血管細胞血管形成之inducers及inhibitors分析。微孔板上包埋Trevigen專利的BME基質及其它組分蛋白，具有極低的細胞毒性，經嚴格的無細菌/真菌/支原體等驗證，接近真實體內環境；螢光定量具更高的精準度。

Cultrex 體外血管生成檢測管形成試劑盒(The Cultrex in vitro Angiogenesis Assay Tube Formation Kit, 3470-096-K) 開發用於評估內皮細胞管形成(endothelial cell tube formation)的誘導劑和抑制劑。在測定過程中，在血管生成調節劑存在的情況下，將內皮細胞(endothelial cells )接種在基底膜提取物(Basement Membrane Extract)的厚凝膠上。如果培養基允許血管生成反應，細胞將在數小時內自行組裝成管網(tube networks)；如果介質中有抑制劑( inhibitors)，管網形成(network formation )將不完整或不存在。在西蘭花和其他十字花科蔬菜中發現的蘿蔔硫素 [1- 異硫氰酸基-(4R)- 甲基亞磺酰基)-丁烷] 是一種天然存在的癌症化學預防劑，並作為對照抑制劑提供以可視化該過程。內皮細胞可以使用 Calcein AM 進行螢光標記，並且可以分析使用顯微鏡相機捕獲的圖像以量化血管生成反應。 Cultrex 體外血管生成檢測試劑盒提供了一種經濟高效的方法，用於研究 96 孔板形式的預期血管生成抑制劑。

​Cultrex® In Vitro Angiogenesis Assay Tube Formation Kit

Catalog #: 3470-096-K 體外血管新生分析套組

癌化過程中具有血管新生之過程，藉以提供癌細胞養份及氧氣。血管新生作用是由內皮細胞所引導的。過程中細胞會分泌酵素來分解基底膜，造成細胞之遊走，經由一連串的增生分化後，最後形成管狀般的血管構造。trevigen提供 Cultrex® In Vitro Angiogenesis Assay Kit ，可以偵測血管細胞血管形成之inducers及inhibitors分析。

Kit Contents

Cultrex^® In Vitro Angiogenesis Assay Tube Formation Kit

Under permissive conditions, endothelial cells respond by self organizing into structures that resemble microvessels or tubes. Trevigen’s Cultrex® In Vitro Angiogenesis Assay Kit allows for the detection of inducers and inhibitors of endothelial cell tube formation. Cultrex^® Reduced Growth Factor (RGF) Basement Membrane Extract (BME) is a soluble form of basement membrane purified from Engelbreth-Holm-Swarm (EHS) tumor, which gels at room temperature to form a reconstituted protein matrix comprised mainly of laminin, collagen IV, entactin, and heparin sulfate proteoglycan. Sulforaphane [1- isothiocyanato-(4R)- methylsulfinyl)-butane], found in broccoli and other cruciferous vegetables, is a naturally occurring cancer chemopreventive agent, and is provided as a control for inhibition of in vitro endothelial cell tube formation on Cultrex^® RGF BME. Calcein AM is provided for rapid and accurate measurement of cell viability and/or cytotoxicity, and kinetic analysis of tube formation. Trevigen’s Cultrex^® In Vitro Angiogenesis Assay Kit provides a cost-effective method for investigation of prospective angiogenesis inhibitors in a 96 well plate format.

Catalog #	Component / Size
3470-096-02	Sulforaphane / 15 μl
4892-010-01	Calcein AM / 50ug  (螢光顯微鏡)
3433-005-01	Cultrex® Reduced Growth Factor Basement Membrane Extract, PathClear® / 5 ml

REFERENCES:

1. Folkman J. 2007. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6:273-286.
   2. Jaffe EA, Nachman RL, Becker CG, Minick CR. 1973. Culture of human endothelial cells derived from umbilical veins. J. Clin. Invest. 52:2745-2756.
   3. Folkman J, Haudenschild C. 1980. Angiogenesis in vitro. Nature 288:551- 556.
   4. Kleinman HK, McGarvey ML, Hassell JR, Star VL, Cannon FB, Laurie GW, Martin GR. 1986. Basement membrane complexes with biological activity. Biochemistry 25:312-318.
   5. Lawley TJ, Kubota Y. 1989. Induction to morphologic differentiation of endothelial cells in culture. J. Invest. Dermatol. 93:59S-61S.
   6. Ucuzian AA, Greisler HP. 2007. In vitro models of angiogenesis. World J. Surg. 31:654-663.
   7. Salcedo R, Zhang X, Young HA, Michael N, Wasserman K, Ma W-H, Martins-Green M, Murphy WJ, Oppenheim JJ. 2003. Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood 102:1966-1977.
   8. Mochizuki M, Philp D, Hozumi K, Suzuki N, Yamada Y, Kleinman HK, Nomizu M. 2007. Angiogenic activity of syndecan-binding laminin peptide AG73 (RKRLQVQLSIRT). Arch. Biochem. Biophys. 459:249-255.
   9. Arnaoutova, I. , J. George, H.K. Kleinman, and G. Benton. 2009. The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art. Angiogensis. 12(3):267-74.
   10. Arnaoutova I, and Kleinman HK. 2010. In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. Nat Protoc. 5(4):628-35.